vitalsign🇦🇺

Joined 2 weeks ago

Account based in Australia

23
Posts
0
Comments
44
Points
All
Comments
Posts
1
STAT+: Eli Lilly and the ‘societal obligation’ of GLP-1s

STAT+: Eli Lilly and the ‘societal obligation’ of GLP-1s

(statnews.com)

Submitted 7 hours ago by vitalsign

0 commentssharesavehidereport
0
1
STAT+: Sarepta Therapeutics shares rise on early promise for rare disease drugs

STAT+: Sarepta Therapeutics shares rise on early promise for rare disease drugs

(statnews.com)

Submitted 14 hours ago by vitalsign

0 commentssharesavehidereport
0
1
Federal vaccine adviser departs ACIP

Federal vaccine adviser departs ACIP

(statnews.com)

Submitted 1 day ago by vitalsign

0 commentssharesavehidereport
0
1
What growing up in an end-times church taught a science communicator about dispelling misinformation

What growing up in an end-times church taught a science communicator about dispelling misinformation

(statnews.com)

Submitted 2 days ago by vitalsign

0 commentssharesavehidereport
0
5
This bill could make CVS choose between its stores and its pharmacy benefit manager

This bill could make CVS choose between its stores and its pharmacy benefit manager

(statnews.com)

Submitted 2 days ago by vitalsign

0 commentssharesavehidereport
0
3
Her son needed a fecal transplant for a fearsome C. diff infection. Getting one required a tortuous journey

Her son needed a fecal transplant for a fearsome C. diff infection. Getting one required a tortuous journey

(statnews.com)

Submitted 3 days ago by vitalsign

0 commentssharesavehidereport
0
3
Opinion: The AI push in health care is deepening medicine’s trust crisis

Opinion: The AI push in health care is deepening medicine’s trust crisis

(statnews.com)

Submitted 3 days ago by vitalsign

0 commentssharesavehidereport
0
5
STAT+: Inside the delicate, high-stakes search for a new CDC director

STAT+: Inside the delicate, high-stakes search for a new CDC director

(statnews.com)

Submitted 5 days ago by vitalsign

0 commentssharesavehidereport
0
6
Drug development is booming in China. Should the U.S. view it as a threat or an opportunity?

Drug development is booming in China. Should the U.S. view it as a threat or an opportunity?

(statnews.com)

Submitted 6 days ago by vitalsign

0 commentssharesavehidereport
0
2
STAT+: Eli Lilly’s ‘triple-G’ shows potency, raises concerns

STAT+: Eli Lilly’s ‘triple-G’ shows potency, raises concerns

(statnews.com)

Submitted 6 days ago by vitalsign

0 commentssharesavehidereport
0

vitalsign

Joined 2 weeks ago
Account based in Australia
🇦🇺
23Posts
0Comments
44Points